Market Research Industry Reports

Irritable Bowel Syndrome - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Irritable Bowel Syndrome - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2018, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 6, 1, 8 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


List of Tables 7
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Irritable Bowel Syndrome - Overview 10
Irritable Bowel Syndrome - Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 18
Irritable Bowel Syndrome - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 26
4D Pharma PLC 26
Allergan Plc 26
Ardelyx Inc 26
ConSynance Therapeutics Inc 27
Cosmo Pharmaceuticals NV 27
Dong-A ST Co Ltd 28
Eisai Co Ltd 28
Enterome Bioscience SA 29
GlaxoSmithKline Plc 29
ImmuneBiotech AB 29
Ironwood Pharmaceuticals Inc 30
Kissei Pharmaceutical Co Ltd 30
Metacrine Inc 31
Napo Pharmaceuticals Inc 31
RaQualia Pharma Inc 31
RedHill Biopharma Ltd 32
SK Biopharmaceuticals Co Ltd 32
Sumitomo Dainippon Pharma Co Ltd 33
Synthetic Biologics Inc 33
Vitality Biopharma Inc 34
Irritable Bowel Syndrome - Drug Profiles 35
BC-1261 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
bedoradrine sulfate - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Blautix - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Canchew Plus - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CIN-103 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
crofelemer DR - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
CSTI-300 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
DA-6886 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
DSP-6952 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
E-2508 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
EB-410 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
EB-420 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
GSK-3179106 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
IB-001 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
linaclotide - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
linaclotide DR2 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
lovastatin MR - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
LT-4006 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
ondansetron hydrochloride CR - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
OP-687 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
ORP-101 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
PR-38 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
RDX-023 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
relenopride hydrochloride - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
rifamycin CR - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
RQ-00310941 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Small Molecules to Inhibit TPH1 for Gastrointestinal, Metabolic Disorder and Oncology - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
solabegron - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
tenapanor - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
VB-210 - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Irritable Bowel Syndrome - Dormant Projects 105
Irritable Bowel Syndrome - Discontinued Products 108
Irritable Bowel Syndrome - Product Development Milestones 109
Featured News & Press Releases 109
Apr 25, 2018: FDA Grants Fast Track Designation for OrphoMeds ORP-101 for Treatment of IBS-D 109
Apr 03, 2018: AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew Product Throughout South Korea 109
Mar 26, 2018: RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA for IBS-D 109
Jan 17, 2018: Outpost Medicine Announces Acceptance of Two Investigational New Drug Applications for OP-687 by U.S. FDA 110
Jan 16, 2018: Sun Pharma Announces Settlement of Patent Litigation for Generic Linzess in US 110
Jan 16, 2018: RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA for IBS-D 110
Jan 04, 2018: OrphoMed Appoints Gastroenterology Expert and Industry Veteran Mark Sostek, M.D. as Chief Medical Officer 111
Jan 03, 2018: Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C 111
Dec 12, 2017: Cosmo Pharmaceuticals Announces First Patient Randomized In Its Proof Of Concept Phase II Clinical Trial Of Rifamycin SV In IBS-D 112
Oct 19, 2017: Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napos FDA-approved Human Prescription Drug 112
Oct 16, 2017: Allergan to Present New Data on Gastrointestinal Drug Candidate Linaclotide at the World Congress of Gastroenterology at ACG 2017 113
Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling 114
Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018 115
Oct 03, 2017: RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with IBS-D 116
Sep 28, 2017: RedHill Biopharma to Announce Top-Line Results from BEKINDA 12 mg Phase II Study for IBS-D on October 3rd, 2017 118
Appendix 119
Methodology 119
Coverage 119
Secondary Research 119
Primary Research 119
Expert Panel Validation 119
Contact Us 119
Disclaimer 120

List Of Tables

List of Tables
Number of Products under Development for Irritable Bowel Syndrome, H1 2018 11
Number of Products under Development by Companies, H1 2018 13
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018 14
Number of Products under Development by Universities/Institutes, H1 2018 15
Products under Development by Companies, H1 2018 16
Products under Development by Companies, H1 2018 (Contd..1), H1 2018 17
Products under Development by Universities/Institutes, H1 2018 18
Number of Products by Stage and Target, H1 2018 20
Number of Products by Stage and Mechanism of Action, H1 2018 22
Number of Products by Stage and Route of Administration, H1 2018 23
Number of Products by Stage and Molecule Type, H1 2018 25
Irritable Bowel Syndrome - Pipeline by 4D Pharma PLC, H1 2018 26
Irritable Bowel Syndrome - Pipeline by Allergan Plc, H1 2018 26
Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2018 27
Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, H1 2018 27
Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, H1 2018 28
Irritable Bowel Syndrome - Pipeline by Dong-A ST Co Ltd, H1 2018 28
Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, H1 2018 28
Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H1 2018 29
Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2018 29
Irritable Bowel Syndrome - Pipeline by ImmuneBiotech AB, H1 2018 30
Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018 30
Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018 31
Irritable Bowel Syndrome - Pipeline by Metacrine Inc, H1 2018 31
Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H1 2018 31
Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, H1 2018 32
Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, H1 2018 32
Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018 33
Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018 33
Irritable Bowel Syndrome - Pipeline by Synthetic Biologics Inc, H1 2018 34
Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H1 2018 34
Irritable Bowel Syndrome - Dormant Projects, H1 2018 105
Irritable Bowel Syndrome - Dormant Projects, H1 2018 (Contd..1), H1 2018 106
Irritable Bowel Syndrome - Dormant Projects, H1 2018 (Contd..2), H1 2018 107
Irritable Bowel Syndrome - Discontinued Products, H1 2018 108

List Of Figures

List of Figures
Number of Products under Development for Irritable Bowel Syndrome, H1 2018 11
Number of Products under Development by Companies, H1 2018 12
Number of Products under Development by Universities/Institutes, H1 2018 15
Number of Products by Top 10 Targets, H1 2018 19
Number of Products by Stage and Top 10 Targets, H1 2018 19
Number of Products by Top 10 Mechanism of Actions, H1 2018 21
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 21
Number of Products by Stage and Routes of Administration, H1 2018 23
Number of Products by Molecule Types, H1 2018 24
Number of Products by Stage and Molecule Types, H1 2018 24

Irritable Bowel Syndrome - Pipeline Review, H1 2018

Irritable Bowel Syndrome - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2018, provides an overview of the

USD 2000View Report

PharmaPoint: Irritable Bowel Syndrome (IBS) - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Irritable Bowel Syndrome (IBS) - Global Drug Forecast and Market Analysis to 2026Irritable bowel syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function.

USD 10995View Report

PharmaPoint: Irritable Bowel Syndrome (IBS) - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Irritable Bowel Syndrome (IBS) - Global Drug Forecast and Market Analysis to 2026Irritable bowel syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function.

USD 10995View Report

Global Irritable Bowel Syndrome Partnering 2012-2018

Provides understanding and access to the irritable bowel syndrome partnering deals and agreements entered into by the worlds leading healthcare companies.

USD 1995View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : May 2018
No. of Pages :120
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube